MSD first company to receive recommendation for drug based on PIP
This article was originally published in SRA
Executive Summary
The antifungal drug Cancidas has become the first medicine to be recommended by the European Medicines Agency (EMEA) for use in children, based on clinical trial data, generated in accordance with an agreed paediatric investigation plan (PIP). The agency’s Committee for Medicinal Products for Human Use (CHMP) recently concluded that the data on the quality, safety and efficacy presented support to an extension of indication for paediatric use.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.